Agenus (AGEN) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Surrozen (SRZN) has outperformed Agenus (AGEN) over the past year, gaining 99.2% versus a gain of 80.8%. Over five years, SRZN leads with a -70.5% price change compared with -92.8% for AGEN. Agenus is the larger company by market cap ($340.5 million vs $328.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | SRZN |
|---|---|---|
| Share price | $7.54 | $27.97 |
| Market cap | $340.52M | $328.75M |
| 1-day change | -0.40% | +11.23% |
| YTD return | +140.13% | +23.76% |
| 1-year return | +80.82% | +99.22% |
| 5-year return | -92.77% | -70.50% |
| P/E ratio (TTM) | 2.98 | — |
| EPS (TTM) | $2.53 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $37.83 |
| 52-week low | $2.71 | $11.39 |
| Distance from 52-week high | -26.87% | -26.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +249.20% | +73.04% |
| Average volume | 4.26M | 483.28K |
| Shares outstanding | 45.16M | 11.75M |
| Employees | 81 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed AGEN by 18.4 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
AGEN vs SRZN FAQ
Which is bigger, Agenus or Surrozen?
Agenus (AGEN) is larger, with a market capitalization of $340.52M compared with $328.75M for Surrozen (SRZN).
Which stock has performed better over the past year, AGEN or SRZN?
SRZN returned +99.22% over the past 12 months, compared with +80.82% for AGEN (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.